The Unmet Needs of Patients with GI Cancer

California Gov. Gavin Newsom signed AB 1682 on Sept. 27, requiring large-group health plans to cover prescribed scalp cooling starting Jan. 1, 2027. Medi-Cal coverage is pending federal approval.

In the phase 3 ASAC trial, daily aspirin did not lower the risk of colorectal cancer returning after treatment for liver metastases, and serious side effects were more common.

Five colorectal cancer trials recently began treating patients, testing targeted drugs, bispecific antibodies and immunotherapy. Here’s what each one is studying.

Medicare's cap on out-of-pocket drug costs has made cancer pills more affordable, but premiums, formularies and prior authorization rules still vary widely. Here's a checklist.

In the phase 2 CO.28 trial, all 4 patients with tumor DNA in their blood after chemotherapy were recommended surgery, versus 38.1% of those without it.

Liver and bile duct cancer treatment has changed quickly since 2021, with new immunotherapy combinations, targeted pills and a new radiation option. Here's what's been approved and what it means for patients.

The FDA has granted two Breakthrough Therapy Designations to AbbVie's investigational drug Temab-A, one for use in metastatic colorectal cancer and one for non-small cell lung cancer, based on early-phase trial data.